<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00552682</url>
  </required_header>
  <id_info>
    <org_study_id>FIBROHIV</org_study_id>
    <nct_id>NCT00552682</nct_id>
  </id_info>
  <brief_title>Pilot, Opened, Randomized Clinical Trial to Assess the Efficacy of Duloxetine in the Treatment of Fibromialgy in Patients With Infection by HIV 1+</brief_title>
  <official_title>Pilot, Opened, Randomized Clinical Trial to Assess the Efficacy of Duloxetine in the Treatment of Fibromialgy in Patients With Infection by HIV 1+</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Germans Trias i Pujol Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare duloxetine with conventional treatment of pain in&#xD;
      HIV-1 infected patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Among HIV-1-infected patients, diagnosis of fibromialgy has increased over the last years .&#xD;
      Appropriate identification of firomialgy in these patients is challenging and sometimes can&#xD;
      be more complicated than in HIV-negative population. Concomitant infectious processes and&#xD;
      symptoms due to HIV infection itself need to be ruled out before establishing a formal&#xD;
      diagnosis.&#xD;
&#xD;
      The treatment of this disease frequently includes muscular relaxants , pain-killers,&#xD;
      anti-inflammatories and antidepressives despite no drug is formally indicated for this&#xD;
      pathology.&#xD;
&#xD;
      Duloxetine approved indications include both treatment of major depressive disorders (MDD)&#xD;
      and diabetic neuropathic pain. Recent studies in HIV negative patients show efficacy to&#xD;
      control pain and depressive symptoms in patients with fibromialgy The main purpose of this&#xD;
      pilot study is to assess the efficacy of duloxetine in HIV-1-infected patients with&#xD;
      fibromialgy.&#xD;
&#xD;
      The main purpose of this pilot study is to assess the efficacy of duloxetine in&#xD;
      HIV-1-infected patients with fibromialgy or chronic fatigue syndrome presenting with&#xD;
      widespread pain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variation in pain measured using the Brief Pain Inventory questionnaire in both branches of the study</measure>
    <time_frame>Time frame: basal visit, weeks 4, 12, 24, 36 and 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess differences in Short-Form 36 Health Survey (SF-36) questionnaire scale score.</measure>
    <time_frame>basal visit, weeks 12, 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess differences in Beck Depression Inventory (BDI) questionnaire scale score.</measure>
    <time_frame>basal visit, weeks 12, 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess differences in Profile of Mood States - Forma A (POMS-A) questionnaire scale score.</measure>
    <time_frame>basal visit, weeks 12, 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the percentage of patients that leave duloxetine due to intolerance or toxicity.</measure>
    <time_frame>basal visit, weeks 4, 12, 24, 36 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess, if possible, pharmacokinetic profile of duloxetine and determine interaction with antiretroviral drugs.</measure>
    <time_frame>basal visit, weeks 4, 12, 24, 36 and 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Fibromyalgia</condition>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duloxetine 60 mg, 1 tablet/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>To continue with the antidepressive treatment if exist</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine 60 mg, QD</intervention_name>
    <description>Duloxetine 60 mg, 1 table/day, 1 year</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Xeristar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged 18 years old and more. Age +18 years old.&#xD;
&#xD;
          2. Documented HIV-1-infection.&#xD;
&#xD;
          3. Former diagnosis of fibromialgy.&#xD;
&#xD;
          4. History of good compliance with visit schedule and medication intake.&#xD;
&#xD;
          5. Patients voluntary signed the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breast-feeding females&#xD;
&#xD;
          2. Suspicion of intolerance to duloxetine.&#xD;
&#xD;
          3. History of any clinical condition that, in the Investigator's criteria, could&#xD;
             potentially reoccur with the suggested change of therapy (sarcoma, lymphoma, etc).&#xD;
&#xD;
          4. Concomitant condition that could mimic fibromialgy (lupus, endocrine diseases,&#xD;
             muscular diseases, multiple sclerosis)&#xD;
&#xD;
          5. or Acute illness within 15 days prior to the inclusion&#xD;
&#xD;
          6. Patients with major depressive disorder with psychotic symptoms, major depressive&#xD;
             disorder melancholic type or bipolar disorder. Patients with other depressive&#xD;
             disorders can be included (dysthymic disorder and depressive disorder NOS)&#xD;
&#xD;
          7. Anorexia or nervous bulimia&#xD;
&#xD;
          8. History or suspected drug or alcohol abuse.&#xD;
&#xD;
          9. Glaucoma&#xD;
&#xD;
         10. History of heart disease including cardiac arrhythmias&#xD;
&#xD;
         11. Severe obesity (body mass index &gt; 45).&#xD;
&#xD;
         12. Concomitant medication with IMAOS, cimetidine or quinolonas&#xD;
&#xD;
         13. Patients with hepatic or renal serious failure (Creatinin clearance &lt;30 ml/min)&#xD;
&#xD;
         14. Patients with Hypericum perforatum as a concomitant treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Negredo Eugenia, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lluita contra la Sida Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Germans Trias i Pujol Hospital</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 31, 2007</study_first_submitted>
  <study_first_submitted_qc>November 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2007</study_first_posted>
  <last_update_submitted>December 3, 2019</last_update_submitted>
  <last_update_submitted_qc>December 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>fibromialgy</keyword>
  <keyword>chronic fatigue syndrome</keyword>
  <keyword>duloxetine</keyword>
  <keyword>pain</keyword>
  <keyword>treatment experienced</keyword>
  <keyword>Fibromialgy in patients with HIV-1 infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Fibromyalgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

